01545nas a2200253   4500000000100000008004100001260001500042653002200057653003100079653002300110653002200133653003200155100002400187700001900211700001700230700001800247700002000265245010100285856007200386300001100458490000700469520080100476022001401277       2024                            d  c2024-06-0110aAI drug discovery10aAI drug in clinical trials10aAI-discovered drug10aAI-native Biotech10aClinical trial success rate1 aMadura KP Jayatunga1 aMargaret Ayers1 aLotte Bruens1 aDhruv Jayanth1 aChristoph Meier00aHow successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons  uhttps://www.sciencedirect.com/science/article/pii/S135964462400134X  a1040090 v293 aAI techniques are making inroads into the field of drug discovery. As a result, a growing number of drugs and vaccines have been discovered using AI. However, questions remain about the success of these molecules in clinical trials. To address these questions, we conducted a first analysis of the clinical pipelines of AI-native Biotech companies. In Phase I we find AI-discovered molecules have an 80–90% success rate, substantially higher than historic industry averages. This suggests, we argue, that AI is highly capable of designing or identifying molecules with drug-like properties. In Phase II the success rate is ∼40%, albeit on a limited sample size, comparable to historic industry averages. Our findings highlight early signs of the clinical potential of AI-discovered molecules.  a1359-6446